Caris Life Sciences™, a leading biosciences company focused on enabling
precise and personalized healthcare, today announced the launch of its
urologic pathology practice, available through its subsidiary Caris Diagnostics.
The addition of this subspecialty, which is being directed by Rajal B.
Shah, M.D., underscores Caris’ commitment to providing high quality,
academic-caliber diagnostic and theranostic services to a broadening list
of subspecialties. Under Dr. Shah’s leadership, Caris’ urologic
pathology experts will also support the development of a revolutionary
and proprietary testing platform that will help diagnose and manage prostate
cancer patients earlier and less invasively.
“Caris’ commitment to precise and personalized healthcare begins
with investment in subspecialty physician expertise. Our urologic pathology
services will mirror our other subspecialty practices with a commitment
to academic activities, including research and education, combined with
unsurpassed service and the latest evidence-based molecular testing,”
said Richard H. Lash, M.D., Chief Medical Officer of Caris Life Sciences.
“We are honored that Dr. Shah will be leading these efforts, bringing
a distinguished academic record to Caris.”
Dr. Shah, who joined the company in January of 2010, as previously announced,
has been named Director of Caris’ Urologic Pathology Services. Dr.
Shah joined Caris from the University of Michigan where he served as Clinical
Associate Professor of Urology and Pathology, as well as Director of the
Urologic Pathology Service and Fellowship Program.
Dr. Shah has been published in more than 90 peer-reviewed journal publications,
speaks frequently at both national and international venues, and has been
the recipient of several NIH-funded grants. In 2007, Dr. Shah was part
of a group of scientists awarded the inaugural “Team Science Award”
from the American Association of Cancer Research for the discovery of
recurrent gene fusions in prostate cancer. The Consumer’s Research
Council of America has selected Dr. Shah as one of America’s Top
The comprehensive diagnostic services offered by the Caris Urologic Pathology
Department include multiplex immunohistochemistry (IHC), full-service
molecular diagnostics, PCA3 testing (molecular urine assay for aiding
prostate cancer detection), and expert second opinion diagnostic services.
More information is available at
About Inform Diagnostics (formerly Caris Diagnostics)
Inform Diagnostics specializes in the development and commercialization
of the highest quality anatomic pathology services, primarily in the fields
of dermatopathology, Hematology/Oncology, gastrointestinal pathology and urologic
pathology. The company’s core team of more than 70 world-leading,
academic-caliber specialists utilize state of the art pathology laboratories
currently headquartered in Irving, TX and throughout the United States
to serve more than 3,000 patients every day. Through rigorous quality
assurance, daily and monthly conferences, and close relationships with
clinical partners, Inform Diagnostics continuously improves diagnostic